Causality assessment for suspected DILI during clinical phases of drug development.
Saved in:
| Title: | Causality assessment for suspected DILI during clinical phases of drug development. |
|---|---|
| Authors: | Regev A; Global Patient Safety, Eli Lilly and Company, Lilly Corporate Center, Drop Code 2121, Indianapolis, IN, 46285, USA, regev_arie@lilly.com., Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB |
| Source: | Drug safety [Drug Saf] 2014 Nov; Vol. 37 Suppl 1, pp. S47-56. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print Cited Medium: Internet ISSN: 1179-1942 (Electronic) Linking ISSN: 01145916 NLM ISO Abbreviation: Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 25352327 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Causality assessment for suspected DILI during clinical phases of drug development. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Regev+A%22">Regev A</searchLink>; Global Patient Safety, Eli Lilly and Company, Lilly Corporate Center, Drop Code 2121, Indianapolis, IN, 46285, USA, regev&#95;arie@lilly.com.<br /><searchLink fieldCode="AU" term="%22Seeff+LB%22">Seeff LB</searchLink><br /><searchLink fieldCode="AU" term="%22Merz+M%22">Merz M</searchLink><br /><searchLink fieldCode="AU" term="%22Ormarsdottir+S%22">Ormarsdottir S</searchLink><br /><searchLink fieldCode="AU" term="%22Aithal+GP%22">Aithal GP</searchLink><br /><searchLink fieldCode="AU" term="%22Gallivan+J%22">Gallivan J</searchLink><br /><searchLink fieldCode="AU" term="%22Watkins+PB%22">Watkins PB</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229002928%22">Drug safety</searchLink> [Drug Saf] 2014 Nov; Vol. 37 Suppl 1, pp. S47-56. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9002928 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1942 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201145916%22">01145916 </searchLink><i>NLM ISO Abbreviation: </i>Drug Saf <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25352327 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s40264-014-0185-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: S47 Titles: – TitleFull: Causality assessment for suspected DILI during clinical phases of drug development. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Regev A – PersonEntity: Name: NameFull: Seeff LB – PersonEntity: Name: NameFull: Merz M – PersonEntity: Name: NameFull: Ormarsdottir S – PersonEntity: Name: NameFull: Aithal GP – PersonEntity: Name: NameFull: Gallivan J – PersonEntity: Name: NameFull: Watkins PB IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2014 Nov Type: published Y: 2014 Identifiers: – Type: issn-electronic Value: 1179-1942 Numbering: – Type: volume Value: 37 Suppl 1 Titles: – TitleFull: Drug safety Type: main |
| ResultId | 1 |